On May 2, 2025, the investment firm HC Wainwright & Co. reaffirmed its positive outlook on Blueprint Medicines (BPMC, Financial) by reiterating its "Buy" rating. The firm also maintained its price target of $135.00, unchanged from their previous analysis. This indicates a continued confidence in the company's future performance.
The analyst responsible for this rating, Andrew Fein, stands by his positive assessment of Blueprint Medicines (BPMC, Financial), supporting the company's strategic direction and growth potential. This latest report comes without any change in the projected price target, emphasizing consistency in valuation.
Blueprint Medicines (BPMC, Financial) continues to hold its ground in the competitive pharmaceutical landscape, attracting supportive views from industry analysts like HC Wainwright & Co. with this reiterated rating.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for Blueprint Medicines Corp (BPMC, Financial) is $125.85 with a high estimate of $167.00 and a low estimate of $83.00. The average target implies an upside of 26.80% from the current price of $99.25. More detailed estimate data can be found on the Blueprint Medicines Corp (BPMC) Forecast page.
Based on the consensus recommendation from 22 brokerage firms, Blueprint Medicines Corp's (BPMC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Blueprint Medicines Corp (BPMC, Financial) in one year is $205.70, suggesting a upside of 107.25% from the current price of $99.25. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Blueprint Medicines Corp (BPMC) Summary page.
